The Protective Variants (PV) working group aims to identify variants, genes, and gene sets that modify the effect of known AD risk factors such as APOE-ε4, age, and sex. Protective genetic factors are a high priority as potential AD therapeutic targets. PV activities focus on APOE-ε4 extremes analyses and deviations from risk predicted by AD models generated from APOE, age, and sex. Analyses use multi-ethnic ADSP and AD genetics community sequencing and genotyping array datasets, as appropriate.
